Chemotherapy-Induced IL34 Enhances Immunosuppression by Tumor-Associated Macrophages and Mediates Survival of Chemoresistant Lung Cancer Cells

Muhammad Baghdadi(Hokkaido University), Haruka Wada(Hokkaido University), Sayaka Nakanishi(Hokkaido University), Hirotake Abe(Hokkaido University), Nanumi Han(Hokkaido University), Wira Eka Putra(Hokkaido University), Daisuke Endo(Hokkaido University), Hidemichi Watari(Hokkaido University), Noriaki Sakuragi(Hokkaido University), Yasuhiro Hida(Hokkaido University), Kichizo Kaga(Hokkaido University), Yohei Miyagi(Kanagawa Prefectural Hospital Organization), Tomoyuki Yokose(Kanagawa Prefectural Hospital Organization), Atsushi Takano(Shiga University of Medical Science), Yataro Daigo(Shiga University of Medical Science), Ken‐ichiro Seino(Hokkaido University)
Cancer Research
August 22, 2016
Cited by 177Open Access
Full Text

Abstract

The ability of tumor cells to escape immune destruction and their acquired resistance to chemotherapy are major obstacles to effective cancer therapy. Although immune checkpoint therapies such as anti-PD-1 address these issues in part, clinical responses remain limited to a subpopulation of patients. In this report, we identified IL34 produced by cancer cells as a driver of chemoresistance. In particular, we found that IL34 modulated the functions of tumor-associated macrophages to enhance local immunosuppression and to promote the survival of chemoresistant cancer cells by activating AKT signaling. Targeting IL34 in chemoresistant tumors resulted in a remarkable inhibition of tumor growth when accompanied with chemotherapy. Our results define a pathogenic role for IL34 in mediating immunosuppression and chemoresistance and identify it as a tractable target for anticancer therapy. Cancer Res; 76(20); 6030-42. ©2016 AACR.


Related Papers

No related papers found

Powered by citation graph analysis